WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012116996) TREATMENT OF ARTERIAL AGEING BY RAAS INHIBITOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/116996    International Application No.:    PCT/EP2012/053378
Publication Date: 07.09.2012 International Filing Date: 28.02.2012
IPC:
A61K 31/122 (2006.01), A61K 31/366 (2006.01), A61K 31/4015 (2006.01), A61K 31/405 (2006.01), A61K 31/41 (2006.01), A61K 31/415 (2006.01), A61K 31/4155 (2006.01), A61K 31/416 (2006.01), A61K 31/422 (2006.01), A61K 31/44 (2006.01), A61K 31/47 (2006.01), A61K 31/505 (2006.01), A61K 31/616 (2006.01), A61P 9/10 (2006.01), A61P 9/14 (2006.01)
Applicants: FARMICOM PHARMACEUTICAL COMPANY D.O.O. [SI/SI]; Obrtna cona Logatec 30 1370 Logatec (SI) (For All Designated States Except US).
ŠABOVIC, Mišo [SI/SI]; (SI) (For US Only)
Inventors: ŠABOVIC, Mišo; (SI)
Agent: LATZEL, Klaus; LATZEL-IP Traunstrasse 3 81825 München (DE)
Priority Data:
P-201100060 28.02.2011 SI
P-201100456 09.12.2011 SI
Title (EN) TREATMENT OF ARTERIAL AGEING BY RAAS INHIBITOR
(FR) TRAITEMENT DU VIEILLISSEMENT ARTÉRIEL PAR L'INHIBITEUR DE RAAS
Abstract: front page image
(EN)The present invention relates to a pharmaceutical combination composition comprising at least one renin-angiotensin-aldosterone system inhibitor, selected from the group consisting of, renin inhibitor, angiotensin-converting enzyme inhibitor and angiotensin II receptor antagonistin in a subtherapeutic daily dose which is designed to prevent and/or to reduce the ageing of the body, particularly for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects.
(FR)La présente invention concerne une composition de combinaisons pharmaceutiques comprenant au moins un inhibiteur du système rénine-angiotensine-aldostérone, sélectionné dans le groupe comprenant l'inhibiteur de la rénine, l'inhibiteur de l'enzyme de conversion de l'angiotensine et un antagoniste du récepteur de l'angiotensine II dans une dose quotidienne sous-thérapeutique. Ladite composition est conçue pour prévenir et/ou atténuer le vieillissement du corps, et peut être notamment utilisée dans la prévention, l'atténuation ou l'inversion du vieillissement artériel chez des sujets apparemment en bonne santé.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)